RxDoctor Payments Data

Rajan Karnani, MD

Neurology · Apple Valley, CANPI 1720018484

Payments from drug & device makers

$6,641in general payments, 2019–2025

Across 290 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • AbbVie$913
  • Teva Pharmaceuticals USA, Inc.$439
  • Amgen$403
  • EMD Serono, Inc.$338
  • Biogen$338
  • plus $3K from 40 others

What the payments were for

  • Speaking & faculty fees$150%
  • Travel & lodging$1,15617%
  • Food & beverage$5,45782%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,641 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$80,403
Medicare patients
198
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate17$170,360
QuliptaAtogepant23$26,638
Nurtec OdtRimegepant Sulfate17$20,119
AptiomEslicarbazepine Acetate16$19,483
NuedextaDextromethorphan Hbr/Quinidine12$18,232
Levetiracetam250$8,336
Carbidopa-LevodopaCarbidopa/Levodopa291$7,525
Primidone326$6,556
Gabapentin501$6,167
Lacosamide34$4,354
Propranolol Hcl ErPropranolol Hcl115$4,330
Divalproex Sodium ErDivalproex Sodium64$2,989
Carbamazepine44$2,519
Topiramate203$2,410
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate11$2,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$338$170,36017 claims
AbbVieQulipta$913$26,63823 claims
PfizerNurtec Odt$15$20,11917 claims
Avanir Pharmaceuticals, Inc.Nuedexta$45$18,23212 claims
Lilly USA, LLCOlanzapine$15$92640 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$31$67517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.

Other neurology in Apple Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →